In the rapidly evolving field of neurodegenerative diseases, a groundbreaking study now unveils a promising biomarker that could revolutionize diagnosis and differentiation of synucleinopathies. Published in the forthcoming 2026 issue of npj Parkinson’s Disease, the study led by Di Fabrizio, M., van der Gaag, B.L., Terzi, M., and colleagues explores the intricate alterations of myelin […]
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.